STOCKS TELEGRAPH

Tag: NASDAQ: ENLV

  • Stocks to Watch as Bulls Take Charge in U.S Equities

    Stocks to Watch as Bulls Take Charge in U.S Equities

    The U.S markets are headed for a good start to the day with the NASDAQ, Dow, and the S&P 500 all in the green in early morning trading.  This is a reflection of the mood across the world where stocks are largely in positive territory today.

    This follows increased optimism for a stimulus package deal for the world’s largest economy. Earlier in September, the Federal Reserve had indicated that a fiscal stimulus package was needed as it had exhausted all monetary policy options for holding the economy together. Despite the improved outlook, investors are still cautious about the impact of COVID-19 on the economy.

    Recently, the number of deaths from the pandemic crossed the 1 million mark. The numbers keep rising too and some countries such as Spain have gone back into lockdown. In the U.S, major corporations such as Disney have announced they are laying off thousands of Staff due to the pandemic.

    The delicate situation is made even more complex by a highly divisive election in just a few weeks. Despite the complexities in the market, there are stocks that are gaining quite strongly and could trade in positive territory all through the day. Some of the stocks to keep an eye on today are as below:

    Enlivex Therapeutics Ltd [NASDAQ: ENLV]

    Enlivex Therapeutics Ltd is a top performer this morning and is up by over 70% pre-market. This follows the company’s announcement that it had got positive results for its COVID-19 treatment called Allocetra in critically ill patients. The trial included 5 people in critical condition who were released after 5.5 days and 8/5 days respectively of using Allocetra. The company also announced that there were no cases of severe side effects related to the use of Allocetra™. The company stated that if the treatment is approved, it would bridge the gap in the treatment of severe and critical COVID-19 patients.

    American Equity Investment Life Holding Company [NYSE: AEL]

    This is another top perfumer this morning and is up by over 50%. This momentum comes just a day after the company announced it had named Graham Day to lead Eagle Life. The company stated that Graham was bringing in two decades of experience in sales leadership to the company. The move has excited the market if the current price action is anything to go by.

    Advanced Emissions Solutions Inc [NASDAQ: ADES]

    Advanced Emissions Solutions Inc is a top performer pre-market and is up by over 40%. This follows the company’s announcement that it had entered into a 15-year activated carbon supply deal with Cabot Corporation.

  • Enlivex (NASDAQ: ENLV) Announces Positive Result Of Allocetra In COVID-19 Patients

    Enlivex (NASDAQ: ENLV) Announces Positive Result Of Allocetra In COVID-19 Patients

    Enlivex Therapeutics Ltd. (NASDAQ: ENLV) has revealed today that the clinical trial of AllocetraTM has shown positive results in COVID-19 patients who were in critical condition. The company has conducted a clinical trial that included five patients, two patients were in critical condition and three patients were in severe condition. But following the treatment of Allocetra all the patients who were in critical and severe conditions were discharged from a hospital after an average of 5.5 days (severe) and 8.5 days (critical).

    The company has further disclosed that there were no severe adverse events were reported relating to the administration of AllocetraTM in the patients, and the therapy was well-tolerated. Other therapies such as plasma-based anti-bodies were used for the treatment of patients in moderate conditions while the company has treated COVID-19 patients who were in severe/critical condition with Allocetra.

    Enlivex Therapeutics Ltd. has believed that the treatment with Allocetra will fill the gap that currently exists in treating severe or critical COVID-19 patients. The biotechnology company revealed that it is planning to recruit more patients who are in severe/critical condition to further check the safety and efficacy of Allocetra after receiving regulatory approval.

    Enlivex Therapeutics Ltd. (NASDAQ: ENLV) shares were trading up 21.22 % at $5.94 at the time of writing on Wednesday. Enlivex Therapeutics Ltd.’s share price went from a low point around $3.59 to briefly over $28.40 in the past 52 weeks, though shares have since pulled back to $5.94. It has moved up 65.46% from its 52-weeks low and moved down -79.08% from its 52-weeks high. ENLV market cap has remained high, hitting $78.23M at the time of writing.

    Head of the Critical Care Medicine Unit at Hadassah Hospital in Israel, and the lead investigator of both the COVID-19 trial and a recently-executed Phase Ib clinical trial of AllocetraTM in sepsis patients, Prof. Vernon van Heerden revealed that the candidate of Enlivex has the potential to treat the COVID-19 patients who are in critical or severe condition. Prof. Vernon said that the five patients with COVID-19 and 10 patients with sepsis have shown the encouraging results in the phase 1b study of Allocetra.

    Enlivex revealed that it is a great opportunity for the company to contribute towards effort aimed at controlling the spread of novel coronavirus. The company will continue its struggle to combat the spread of COVID-19. It is anticipated that the Phase IIb trial of Allocetra will commence in the fourth quarter of the company.